Alamar Biosciences, Inc.

ALMR·NasdaqGS·Healthcare
Compare
24.24−1.03 (−4.08%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours24.240.00 (0.00%)Oct 12, 4:39 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close25.27
Open25.07
Day range23.5726.70
52-week range18.8539.61
Off day high−9.21%
Off 52-week high−38.80%
Volume1.03M
Avg. volume (3M)434.27K
Market cap1.68B
EPS (TTM)-1.20
Forward P/E-44.69
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding69.39M
Short interest6.57% of float
Earnings dateNov 3, 2026
Analyst target35.40
Profit margin−49.45%

Against its peers

Compare in full ›
ALMR LAB NEOG CTKB BIO QSI
Market cap 1.68B 258.24M 2.62B 690.21M 9.74B 297.68M
P/E (TTM) — — — — 46.2 —
Forward P/E -44.7 -65.8 28.8 75.9 36.7 -3.9
Price/book 5.4 0.5 1.3 2.1 1.4 1.7
Dividend yield — — — — — —
1-year change +10.18% −48.84% +99.16% +37.12% +20.56% −26.44%
Today −4.08% −4.58% +1.27% −2.21% −0.48% −11.11%

The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.

Latest news

All ALMR news ›
markets.businessinsider.com·Positive

Alamar Biosciences rises 9.4%

Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02. Published first on TheFly – the ultimate source for real-time, market-moving breaking... Alamar Biosciences rises 9.4% Alamar Biosciences (ALMR) is up 9.4%, or $3.01 to $35.02.…

markets.businessinsider.com·Positive

Alamar Biosciences price target raised to $31 from $30 at BofA

BofA raised the firm’s price target on Alamar Biosciences (ALMR) to $31 from $30 and keeps a Neutral rating on the shares. A “strong” Q2 report ... Alamar Biosciences price target raised to $31 from $30 at BofA BofA raised the firm’s price…

Seeking Alpha·Positive

Alamar: The Consumables Flywheel Is Just Getting Started

Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. Learn more about ALMR stock here. - Alamar Biosciences is rated a buy, targeting a recurring consumables-driven…

From articles in the 4Search news index.

In the news

12mentions in 30 days
11with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.